Compare BAOS & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAOS | JAGX |
|---|---|---|
| Founded | 2018 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6M | 3.9M |
| IPO Year | 2021 | N/A |
| Metric | BAOS | JAGX |
|---|---|---|
| Price | $2.90 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | 65.4K | ★ 387.2K |
| Earning Date | 12-26-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $860,951.00 | ★ $11,785,000.00 |
| Revenue This Year | N/A | $22.41 |
| Revenue Next Year | N/A | $30.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.20 | ★ 12.45 |
| 52 Week Low | $1.44 | $1.00 |
| 52 Week High | $13.66 | $33.25 |
| Indicator | BAOS | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 45.52 | 42.77 |
| Support Level | $2.88 | $1.05 |
| Resistance Level | $3.80 | $1.36 |
| Average True Range (ATR) | 0.20 | 0.15 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 6.06 | 43.00 |
Baosheng Media Group Holdings Ltd operates as a V-log streaming marketing service provider. The firm offers comprehensive marketing solutions. Its services are Internet effect marketing, V-log or short video streaming marketing including content production and operation, e-commerce marketing, original data platform system service, and AI technology. It provides one-stop and full-link deep customized marketing solutions for partners. Baosheng Group is also a core agency of domestic Internet companies such as Tencent, Alibaba, Bytedance, and Kuaishou, with performing channel marketing services, technologies, and applications.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.